What’s in Merck and Moderna’s cancer vaccine algorithm?

NewsletterThe Readout What’s in Merck and Moderna’s cancer vaccine algorithm? A heart drug failure, RevMed’s pancreatic cancer drug approved, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanAug. 27, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we look at how a China biotech crackdown could benefit Europe, what a rival drug failure might mean for Alnylam, the algorithm behind the Moderna-Merck cancer vaccine, and a landmark approval in pancreatic cancer.Advertisement RIP, Tim Curry.

I shall mourn how humbly you buttle. The need-to-know this morning Moderna is raising $2 billion in convertible debt. The new financing comes one week after the Phase 3 success of its personalized cancer vaccine.

The power of the Moderna-Merck cancer vaccine may hinge on an algorithm Moderna and Merck’s personalized cancer vaccine could become the first approved medicine whose genetic instructions are essentially written by an algorithm. For each patient, software analyzes thousands of tumor mutations and chooses 34 neoantigens to encode into a bespoke mRNA vaccine — a regulatory and computational experiment that some researchers now believe could be the treatment’s “secret sauce.” That said, some skeptical Wall Street investors think that perhaps the personalization isn’t necessary at all, and that mRNA itself primes tumors to respond better to Keytruda. So what’s in that algorithm?

Advertisement “I have no idea,” said Alex Rubinsteyn, a cancer vaccine expert at the University of North Carolina. “Everyone claims what they have is proprietary intelligence.” Read more. U.S.

crackdown on Chinese biotech could benefit Europe A bipartisan bill aimed at limiting U.S. biotech ties with China could end up handing Europe a competitive advantage, executives from the Croatia-based CRO Optimapharm opine for STAT. The proposed Biotech Investment National Security Act, or BINSA, would broaden federal oversight of U.S.

investment and dealmaking with Chinese biotech companies. However, Optimapharm’s argue, companies could simply route the drugs discovered in China through European sponsors — a strategy dubbed “Eurowashing.” This potentially could shift licensing profits, tax revenue, and clinical development activity away from the U.S. Also, biotechs often default to crowded U.S., Australian, and Western European trial sites rather than considering faster and cheaper alternatives in Central and Eastern Europe.

Whether BINSA passes or not, the executives say, companies should diversify their clinical trial strategies now before geopolitical tensions make those decisions for them. Read more. A heart drug failure casts shadow over Alnylam The European Society of Cardiology Congress in Munich could offer crucial clues about the future of Alnylam’s ATTR-CM franchise, STAT’s Adam Feuerstein writes.

AstraZeneca and Ionis will reveal details on why their rival gene-silencing drug, eplontersen, failed a pivotal Phase 3 study. The drug showed no cardiovascular benefit when added to widely used stabilizer drugs — which suggests that injectable gene silencers may not add much benefit to much to easier-to-use oral treatments. This will matter for Alnylam’s blockbuster, Amvuttra, and especially next-generation nucresiran, now in Phase 3 testing.

Alnylam says nucresiran’s greater potency and differently designed trial can succeed where eplontersen stumbled, but investors aren’t entirely convinced. Read more. FDA approves landmark pancreatic cancer drug The FDA has approved the buzzy pancreatic cancer drug made by Revolution Medicines.

Rasonque is the first treatment to attack a genetic driver of pancreatic cancer — and what oncologists are calling the disease’s biggest therapeutic advance in decades. Advertisement In a pivotal trial, the RAS-targeting drug nearly doubled median survival to 13.2 months from 6.7 months with chemotherapy in previously treated patients. This establishes a new standard of care for a cancer with a dismal 8% five-year survival rate.

The approval also caps a decades-long effort to drug the once-considered “undruggable” RAS proteins and transforms Revolution into a leader in targeted cancer medicines. The drug will cost $39,800 per month and carries substantial skin and mouth toxicities, and patients eventually develop resistance. But it could potentially have benefits in other RAS-driven tumors, including lung and colorectal cancers.

Read more. More reads Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate, FiercePharma JATT mastermind launches latest biotech-focused SPAC via $60 million IPO, FierceBiotech Biohaven strikes $795M deal for commercial partner in epilepsy, Endpoints biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Adam's Biotech Scorecard August 27, 2026 STAT Plus: Alnylam’s heart drug troubles take center stage at a cardiology conference Biotech August 27, 2026 STAT Plus: The mystery of Moderna’s magic algorithm Advertisement Opinions+ August 27, 2026 STAT Plus: A bill is supposed to protect U.S.

biotech from Chinese competition. But there’s a loophole Biotech August 26, 2026 STAT Plus: FDA approves new pancreatic cancer drug expected to usher in new era of treatment The Readout August 26, 2026 STAT Plus: Key data on a new class of cardio drugs are coming Subscriber Picks